Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + toripalimab + GEMOX first-line study in advanced intrahepatic cholangiocarcinoma
ChiCTR2300073731Phase 4Not yet recruiting
- Sponsor
- The First College of Clinical Medical Science, China Three Gorges University
- Start
- Aug 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of surufatinib, toripalimab, gemcitabine and oxaliplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by The First College of Clinical Medical Science, China Three Gorges University. Primary endpoint: Progression-free survival. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
surufatinibtoripalimabgemcitabineoxaliplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2300073731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073731.